Tocilizumab for treating juvenile idiopathic arthritis

Expert Opinion on Biological Therapy

Volumn 16, Issue 4, 2016, Pages 559-566

  Turnier, Jessica L ^a   Brunner, Hermine I ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Interleukin 6; Juvenile Idiopathic Arthritis; Tocilizumab

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 6; TOCILIZUMAB; ANTIRHEUMATIC AGENT; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

ANAPHYLAXIS; AREA UNDER THE CURVE; CLINICAL STUDY; DIARRHEA; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; JUVENILE RHEUMATOID ARTHRITIS; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MONOTHERAPY; NEUTROPENIA; NONHUMAN; PANCYTOPENIA; PATHOGENESIS; PHARMACODYNAMICS; PHARYNGITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOLUME OF DISTRIBUTION; ANTAGONISTS AND INHIBITORS; ARTHRITIS, JUVENILE; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; HUMANS; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION;

EID: 84959227338     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2016.1150997     Document Type: Review

References (67)

1. Harrold LR, Salman C, Shoor S, et al. Incidence and prevalence of juvenile idiopathic arthritis among children in a managed care population, 1996-2009. J Rheumatol. 2013;40:1218-1225. doi:10. 3899/ jrheum. 120661.
2. Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390-392.
3. Martini A. Systemic juvenile idiopathic arthritis. Autoimmun Rev. 2012;12:56-59. doi:10. 1016/j. autrev. 2012. 07. 022.
4. Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005;146:598-604. doi:10. 1016/j. jpeds. 2004. 12. 016.
5. Guzman J, Oen K, Tucker LB, et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis. 2015;74:1854-1860. doi:10. 1136/annrheumdis-2014-205372.
6. Sen ES, Dick AD, Ramanan AV. Uveitis associated with juvenile idiopathic arthritis. Nat Rev Rheumatol. 2015;11:338-348. doi:10. 1038/nrrheum. 2015. 20.
7. Saurenmann RK, Levin AV, Feldman BM, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheum. 2007;56:647-657. doi:10. 1002/art. 22381.
8. Otten MH, Anink J, Prince FH, et al. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register. Ann Rheum Dis. 2015;74:1379-1386. doi:10. 1136/ annrheumdis-2013-204641
9. Bingham C, Ardoin SP, Vora S, et al. A1: clinical inactive disease in the pediatric rheumatology care and outcomes improvement network cohort: which components of clinical inactive disease do patients not achieve Arthritis Rheum. 2014;66:S1-S2. doi:10. 1002/art. 38412.
10. Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res. 2014;2:288-294. doi:10. 1158/ 2326-6066. CIR-14-0022.
11. Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol. 2012;52:199-219. doi:10. 1146/annurev-pharmtox-010611-134715.
12. De Benedetti F, Massa M, Robbioni P, et al. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991;34:1158-1163.
13. Pignatti P, Vivarelli M, Meazza C, et al. Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis. J Rheumatol. 2001;28:1670-1676.
14. Rooney M, David J, Symons J, et al. Inflammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol. 1995;34:454-460.
15. Boe A, Baiocchi M, Carbonatto M, et al. Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine. 1999;11:1057-1064. doi:10. 1006/cyto. 1999. 0502.
16. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998;102:1369-1376. doi:10. 1172/JCI2629.
17. Schulert GS, Grom AA. Macrophage activation syndrome and cytokine-directed therapies. Best Pract Res Clin Rheumatol. 2014;28:277-292. doi:10. 1016/j. berh. 2014. 03. 002.
18. Strippoli R, Carvello F, Scianaro R, et al. Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome. Arthritis Rheum. 2012;64:1680-1688. doi:10. 1002/art. 33496.
19. Cifaldi L, Prencipe G, Caiello I, et al. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. Arthritis Rheumatol. 2015;67:3037-3046. doi:10. 1002/art. 39295.
20. Scheller J, Chalaris A, Schmidt-Arras D, et al. The pro-and anti-inflammatory properties of the cytokine interleukin-6. BiochimBiophys Acta. 2011;1813:878-888. doi:10. 1016/j. bbamcr. 2011. 01. 034.
21. De Benedetti F, Massa M, Pignatti P, et al. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest. 1994;93:2114-2119. doi:10. 1172/JCI117206.
22. Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine. 2014;70:11-20. doi:10. 1016/j. cyto. 2014. 05. 024.
23. Jones SA, Richards PJ, Scheller J, et al. IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res. 2005;25:241-253. doi:10. 1089/jir. 2005. 25. 241.
24. Sato K, Tsuchiya M, Saldanha J, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 1993;53:851-856.
25. Tanaka T, Narazaki M, Kishimoto T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett. 2011;585:3699-3709. doi:10. 1016/j. febslet. 2011. 03. 023.
26. Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5:1731-1740. doi:10. 1016/j. intimp. 2005. 05. 010.
27. Actemra (tocilizumab) injection, for intravenous use [Prescribing information]. South San Francisco (CA): Genentech; 2014. Available from: http://www. gene. com/download/pdf/actemra-pre scribing. pdf
28. Zhang X, Morcos PN, Saito T, et al. Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis. Expert Rev Clin Pharmacol. 2013;6:123-137. doi:10. 1586/ecp. 13. 1. This is the best review article we found for the pharmacology of tocilizumab in treatment of juvenile idiopathic arthritis (JIA).
29. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998-1006. doi:10. 1016/S0140-6736(08)60454-7.
30. Zhang X, Morcos PN, De Benedetti F, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of tocilizumab (TCZ) in systemic juvenile idiopathic arthritis (sJIA). Clinical Pharmacology & Therapeutics. 2011;89:S36.
31. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385-2395. doi:10. 1056/NEJMoa1112802.
32. Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74:1110-1117. doi:10. 1136/annrheumdis-2014-205351.
33. Decelle K, Horton ER. Tocilizumab for the treatment of juvenile idiopathic arthritis. Ann Pharmacother. 2012;46:822-829. doi:10. 1345/ aph. 1Q756.
34. Kivitz A, Olech E, Borofsky M, et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66:1653-1661. doi:10. 1002/acr. 22384.
35. Uchiyama Y, Yoshida H, Koike N, et al. Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production. Int Immunopharmacol. 2008;8:1595-1601. doi:10. 1016/j. intimp. 2008. 07. 002.
36. Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112:3959-3964. doi:10. 1182/blood-2008-05-155846.
37. Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:818-825. doi:10. 1002/art. 20944.
38. Yokota S, Imagawa T, Mori M, et al. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J Rheumatol. 2014;41:759-767. doi:10. 3899/jrheum. 130690.
39. Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7:R1281-1288.
40. Imagawa T, Yokota S, Mori M, et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol. 2012;22:109-115. doi:10. 1007/s10165-011-0481-0.
41. Lovell DJ, Ruperto N, Giannini EH, et al. Advances from clinical trials in juvenile idiopathic arthritis. Nat Rev Rheumatol. 2013;9:557-563. doi:10. 1038/nrrheum. 2013. 105.
42. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202-1209. doi:10. 1002/1529-0131(199707)40:7<1202::AID-ART33. 0. CO;2-R.
43. De Benedetti F, Brunner H, Allen R, et al. Tocilizumab is efficacious in patients with systemic juvenile idiopathic arthritis across baseline demographic and disease characteristics and prior/baseline treatments: 52-week data from a phase 3 clinical trial. In: Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals. Arthritis and Rheumatism. 2011;63(10 Suppl. 1).
44. De Benedetti F, Ruperto N, Brunner H, et al. A6: tapering and withdrawal of tocilizumab in patients with systemic juvenileidiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER Study. Arthritis Rheum. 2014;66:S8-9 10. 1002/art. 38417
45. De Benedetti F, Brunner H. FRI0328 Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): 2-year data from tender, a phase 3 clinical trial. Ann Rheum Dis. 2012;71:425. doi:10. 1136/annrheumdis-2012-eular. 2785.
46. De Benedetti F, Brunner H, Ruperto N, et al. Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial. Arthritis Rheumatol. 2015;67:840-848. doi:10. 1002/art. 38984.
47. Inaba Y, Ozawa R, Imagawa T, et al. Radiographic improvement of damaged large joints in children with systemic juvenile idiopathic arthritis following tocilizumab treatment. Ann Rheum Dis. 2011;70:1693-1695. doi:10. 1136/ard. 2010. 145359.
48. Inaba Y, Ozawa R, Aoki C, et al. Radiologic analysis of the effect of tocilizumab on hands and large joints in children with systemic juvenile idiopathic arthritis. Mod Rheumatol. 2013;23:667-673. doi:10. 1007/s10165-012-0711-0.
49. Aoki C, Inaba Y, Choe H, et al. Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis. J Rheumatol. 2014;41:1171-1177. doi:10. 3899/jrheum. 130924.
50. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88-96. doi:10. 1136/ard. 2008. 105197.
51. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013;72:43-50. doi:10. 1136/annrheumdis-2011-201282.
52. Tozawa Y, Fujita S, Abe S, et al. Radiological improvement by tocilizumab in polyarticular juvenile idiopathic arthritis. Pediatr Int. 2015;57:307-310. doi:10. 1111/ped. 12454.
53. Yokota S, Itoh Y, Morio T, et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis. 2015. doi:10. 1136/annrheumdis-2015-207818. [Epub ahead of print].
54. Kessler EA, Vora SS, Verbsky JW. Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome. Pediatr Rheumatol Online J. 2012;10:30. doi:10. 1186/1546-0096-10-24.
55. Yokota S, Itoh Y, Morio T, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab. J Rheumatol. 2015;42:712-722. doi:10. 3899/ jrheum. 140288.
56. Shimizu M, Nakagishi Y, Kasai K, et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine. 2012;58:287-294. doi:10. 1016/j. cyto. 2012. 02. 006.
57. Wallace CA, Giannini EH, Spalding SJ, et al. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. J Rheumatol. 2014;41:1163-1170. doi:10. 3899/jrheum. 131503.
58. Wallace CA, Ringold S, Bohnsack J, et al. Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis. J Rheumatol. 2014;41:2459-2465. doi:10. 3899/ jrheum. 140347.
59. Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70:747-754. doi:10. 1136/ard. 2010. 134254.
60. Gattorno M, Piccini A, Lasiglie D, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008;58:1505-1515. doi:10. 1002/art. 23437.
61. Sieper J, Porter-Brown B, Thompson L, et al. Assessment of shortterm symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis. 2014;73:95-100. doi:10. 1136/annrheumdis-2013-203559.
62. Tsang AC, Roth J, Gottlieb C. Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient. Ocul Immunol Inflamm. 2014;22:155-157. doi:10. 3109/ 09273948. 2013. 866254.
63. Papo M, Bielefeld P, Vallet H, et al. Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol. 2014;32: S75-79.
64. Garbers C, Aparicio-Siegmund S, Rose-John S. The IL-6/gp130/ STAT3 signaling axis: recent advances towards specific inhibition. Curr Opin Immunol. 2015;34:75-82. doi:10. 1016/j. coi. 2015. 02. 008.
65. Bravo Mancheno B, Perin F, Guez Vazquez Del Rey MDM, et al. Successful tocilizumab treatment in a child with refractory Takayasu arteritis. Pediatrics. 2012;130:e1720-1724. doi:10. 1542/ peds. 2012-1384.
66. Addimanda O, Pipitone N, Pazzola G, et al. Tocilizumab for severe refractory neuro-Behcet: three cases IL-6 blockade in neuro-Behcet. Semin Arthritis Rheum. 2015;44:472-475. doi:10. 1016/j. semarthrit. 2014. 08. 004.
67. Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014;82:1302-1306. doi:10. 1212/WNL. 0000000000000317.